Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.

A huge leap in fines for misusing mobility parks, help with childcare and access to new drugs are just some of the measures ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In a triple whammy of good news, 1 October heralds the beginning of the funding of two major health products and a welcome contribution to early childhood fees, Prime Minister Christopher Luxon says.

A total of 27 women received the breast cancer vaccine and the clinical trial is preparing its second phase. Results are ...

Merck (MRK) is one of the worst-performing stocks in the Dow Jones Industrial Average (DJIA) on Thursday. The US government ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

“Keytruda is the first drug to be funded and made available from the $604 million boost we made to Pharmac in June. It will be life-changing for people with advanced triple-negative breast ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...